ZA202102544B - Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof - Google Patents

Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof

Info

Publication number
ZA202102544B
ZA202102544B ZA2021/02544A ZA202102544A ZA202102544B ZA 202102544 B ZA202102544 B ZA 202102544B ZA 2021/02544 A ZA2021/02544 A ZA 2021/02544A ZA 202102544 A ZA202102544 A ZA 202102544A ZA 202102544 B ZA202102544 B ZA 202102544B
Authority
ZA
South Africa
Prior art keywords
preparation
ligand
drug conjugate
method therefor
exatecan
Prior art date
Application number
ZA2021/02544A
Other languages
English (en)
Inventor
Xu Jianyan
Zhang Ying
Cai Xiaofeng
Qu Bolei
Liang Jindong
Zhang Lianshan
He Feng
Tao Weikang
Original Assignee
Jiangsu Hengrui Medicine Co
Shanghai hengrui pharmaceutical co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co, Shanghai hengrui pharmaceutical co ltd filed Critical Jiangsu Hengrui Medicine Co
Publication of ZA202102544B publication Critical patent/ZA202102544B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA2021/02544A 2018-09-26 2021-04-16 Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof ZA202102544B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201811123833 2018-09-26
PCT/CN2019/107873 WO2020063676A1 (zh) 2018-09-26 2019-09-25 依喜替康类似物的配体-药物偶联物及其制备方法和应用

Publications (1)

Publication Number Publication Date
ZA202102544B true ZA202102544B (en) 2023-10-25

Family

ID=69953349

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2021/02544A ZA202102544B (en) 2018-09-26 2021-04-16 Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof

Country Status (13)

Country Link
US (1) US20210353764A1 (https=)
EP (1) EP3858386A4 (https=)
JP (1) JP7558156B2 (https=)
KR (1) KR20210066833A (https=)
CN (4) CN118903456A (https=)
AU (1) AU2019349207B2 (https=)
BR (1) BR112021004656A2 (https=)
CA (1) CA3114137A1 (https=)
MX (1) MX2021003382A (https=)
TW (1) TWI826543B (https=)
UA (1) UA130338C2 (https=)
WO (1) WO2020063676A1 (https=)
ZA (1) ZA202102544B (https=)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112543771B (zh) * 2018-09-30 2023-04-11 江苏豪森药业集团有限公司 抗b7h3抗体-依喜替康类似物偶联物及其医药用途
CN111689980A (zh) * 2019-05-26 2020-09-22 四川百利药业有限责任公司 一种喜树碱药物及其抗体偶联物
MX2021014960A (es) * 2019-06-06 2022-03-04 Shanghai Hansoh Biomedical Co Ltd Conjugado de farmaco-anticuerpos anti-b7-h4 y uso medicinal del mismo.
AU2020402006A1 (en) * 2019-12-12 2022-07-07 Jiangsu Hengrui Medicine Co., Ltd. Anti-claudin antibody-drug conjugate and pharmaceutical use thereof
CN118949063A (zh) 2020-01-22 2024-11-15 上海森辉医药有限公司 艾日布林衍生物的药物偶联物、其制备方法及其在医药上的应用
AU2021213421B2 (en) 2020-01-31 2025-02-06 Innate Pharma Treatment of cancer
JP7689979B2 (ja) * 2020-03-25 2025-06-09 江蘇恒瑞医薬股▲ふん▼有限公司 抗体薬物複合体を含む医薬組成物及びその使用
BR112022019042A2 (pt) * 2020-03-25 2022-11-01 Jiangsu Hengrui Pharmaceuticals Co Ltd Método de preparação para conjugado anticorpo-fármaco
CA3177279A1 (en) * 2020-03-25 2021-09-30 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-psma antibody-exatecan analogue conjugate and medical use thereof
CA3186295A1 (en) 2020-06-08 2021-12-16 Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. Camptothecin drug having high-stability hydrophilic connecting unit and conjugate thereof
KR20240038138A (ko) 2020-07-13 2024-03-22 리제너론 파마슈티칼스 인코포레이티드 단백질에서 글루타민 잔기에 접합된 캄토테신 유사체 및 그의 용도
MX2023001163A (es) 2020-07-27 2023-02-22 Tuojie Biotech Shanghai Co Ltd Conjugado de farmaco anticuerpo anti-cd79b, metodo de preparacion y uso farmaceutico del mismo.
BR112023002417A2 (pt) * 2020-08-13 2023-03-21 Chia Tai Tianqing Pharmaceutical Group Co Ltd Conjugado de anticorpo e fármaco
JP7780953B2 (ja) * 2020-09-15 2025-12-05 バイリ－バイオ（チェンドゥ）ファーマスーティカル シーオー．，エルティーディー． カンプトテシン類医薬品及びその抗体複合体
CN114249798A (zh) * 2020-09-24 2022-03-29 江苏恒瑞医药股份有限公司 一种依喜替康类似物的结晶形式及其制备方法
MX2023003778A (es) 2020-09-30 2023-04-26 Duality Biologics Suzhou Co Ltd Compuesto antitumoral, metodo de preparacion y uso del mismo.
KR20230079096A (ko) 2020-09-30 2023-06-05 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 항체-약물 접합체를 포함하는 약제학적 조성물 및 약제학적 조성물의 용도
EP4227309A4 (en) * 2020-10-12 2024-11-27 Sichuan Baili Pharmaceutical Co. Ltd. DEUTERATED CAMPTOTHECIN DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF
US20250276078A1 (en) 2020-10-12 2025-09-04 Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. Camptothecin Derivative And Ligand-drug Conjugate Thereof
CN116133694B (zh) * 2020-10-14 2026-03-06 苏州盛迪亚生物医药有限公司 抗her3抗体和抗her3抗体药物偶联物及其医药用途
WO2022099762A1 (zh) * 2020-11-12 2022-05-19 博瑞生物医药（苏州）股份有限公司 一种抗体偶联物中间体及其制备方法
US20230416270A1 (en) * 2020-12-11 2023-12-28 Wigen Biomedicine Technology (shanghai) Co., Ltd. Novel camptothecin derivative, composition comprising same and use thereof
CN114652853B (zh) * 2020-12-22 2024-09-13 江苏恒瑞医药股份有限公司 抗il-4r抗体-药物偶联物及医药用途
CN116568707A (zh) * 2021-01-29 2023-08-08 上海翰森生物医药科技有限公司 一种抗体药物偶联物及其医药用途
KR20250120438A (ko) * 2021-02-05 2025-08-08 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 캄프토테신 화합물, 그의 제조방법 및 그의 응용
CN116888123B (zh) * 2021-02-09 2026-02-24 微境生物医药科技(上海)有限公司 用于adc制备的喜树碱衍生物
TW202300148A (zh) * 2021-03-17 2023-01-01 大陸商江蘇恒瑞醫藥股份有限公司 喜樹鹼衍生物的製備方法
CN115197088A (zh) * 2021-04-02 2022-10-18 江苏恒瑞医药股份有限公司 一种喜树碱衍生物中间体的制备方法
CN115197234A (zh) * 2021-04-02 2022-10-18 江苏恒瑞医药股份有限公司 一种喜树碱衍生物中间体的制备方法
CN117157304A (zh) * 2021-04-15 2023-12-01 江苏恒瑞医药股份有限公司 一种依喜替康类似物的结晶形式及其制备方法
US20240269307A1 (en) * 2021-04-26 2024-08-15 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-nectin-4 antibody and anti-nectin-4 antibody-drug conjugate, and medicinal use thereof
CN113816969B (zh) * 2021-04-30 2024-01-16 联宁（苏州）生物制药有限公司 依喜替康类化合物、其抗体药物偶联物及其应用
BR112023023276A2 (pt) * 2021-05-07 2024-01-30 Alx Oncology Inc Derivados de exatecan e conjugados anticorpo-fármaco destes
CN115385926B (zh) * 2021-05-24 2025-06-03 上海复旦张江生物医药股份有限公司 一种连接基药物偶联物的制备方法及其中间体
CN115557962A (zh) * 2021-07-02 2023-01-03 石药集团巨石生物制药有限公司 新型喜树碱类化合物及其制备方法和应用
TW202320858A (zh) 2021-07-19 2023-06-01 美商薩諾管理公司 免疫接合物及方法
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
MX2024000895A (es) 2021-07-21 2024-02-06 Jiangsu Hengrui Pharmaceuticals Co Ltd Composicion farmaceutica que contiene el conjugado del farmaco anticuerpo anti-trop2 y su aplicacion.
CN115850291B (zh) * 2021-09-24 2024-11-15 石药集团巨石生物制药有限公司 喜树碱衍生物及其用途
CA3232764A1 (en) 2021-09-30 2023-04-06 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pyrrolo benzodiazepine derivative, and conjugate, preparation method and use thereof
WO2023061472A1 (zh) * 2021-10-14 2023-04-20 江苏恒瑞医药股份有限公司 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途
EP4434548A1 (en) 2021-11-15 2024-09-25 Systimmune, Inc. Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof
US11814394B2 (en) 2021-11-16 2023-11-14 Genequantum Healthcare (Suzhou) Co., Ltd. Exatecan derivatives, linker-payloads, and conjugates and thereof
AU2022389555A1 (en) * 2021-11-17 2024-07-04 CSPC Megalith Biopharmaceutical Co., Ltd. Antibody-drug conjugate and use thereof
CN116212044A (zh) 2021-12-03 2023-06-06 成都百利多特生物药业有限责任公司 抗人Trop2抗体-喜树碱类药物偶联物及其医药用途
CN118414339A (zh) * 2021-12-16 2024-07-30 迈威(上海)生物科技股份有限公司 一种喜树碱类化合物及其偶联物
CN118302448A (zh) 2021-12-28 2024-07-05 江苏恒瑞医药股份有限公司 抗ror1抗体和抗ror1抗体药物偶联物及其医药用途
JP2025504419A (ja) 2022-01-26 2025-02-12 上▲海▼▲邁▼晋生物医▲薬▼科技有限公司 抗ＣＤ７９ｂ抗体薬物複合体を含む医薬組成物及びその使用
AU2023213783A1 (en) * 2022-01-28 2024-08-15 Duality Biologics (Suzhou) Co., Ltd. Her3 antibody-drug conjugate and use thereof
WO2023174401A1 (zh) * 2022-03-18 2023-09-21 映恩生物制药（苏州）有限公司 Gpc3抗体药物偶联物及其用途
JP7667870B2 (ja) 2022-03-25 2025-04-23 バイリ－バイオ（チェンドゥ）ファーマスーティカル シーオー．，エルティーディー． Ｄｎａ毒性二量体及びその複合体
KR20250009592A (ko) * 2022-04-12 2025-01-17 미네르바 바이오테크놀로지 코포레이션 항-가변 muc1* 항체 및 그의 용도
CA3250941A1 (en) 2022-04-29 2025-03-20 Systimmune, Inc. Conjugated ligand-drug containing a hydrophilic sugar structure
EP4514350A1 (en) * 2022-04-29 2025-03-05 Shanghai MicuRx Pharmaceutical Co., Ltd. Ligand-drug conjugate of camptothecin analogs, intermediates, preparation method therefor, pharmaceutical composition and application thereof
WO2023217227A1 (zh) 2022-05-12 2023-11-16 先声再明医药有限公司 喜树碱类衍生物及配体-药物偶联物
CN119013302A (zh) 2022-05-16 2024-11-22 江苏恒瑞医药股份有限公司 一种含抗Nectin-4抗体药物偶联物的药物组合物及其用途
CA3254333A1 (en) 2022-05-18 2025-07-04 Systimmune, Inc. Ligand-drug conjugate and use thereof
JP2025523382A (ja) 2022-06-07 2025-07-23 デュアリティ― バイオロジックス（スージョウ）シーオー．エルティーディー． 抗ｂ７ｈ３抗体－薬物複合体及びその使用
JP2025519421A (ja) * 2022-06-09 2025-06-26 ベイジーン スイッツァランド ゲーエムベーハー 抗体薬物複合体
CN118955615B (zh) * 2022-07-05 2026-01-30 上海药明合联生物技术有限公司 偶联连接子
KR20250075560A (ko) 2022-07-15 2025-05-28 진콴텀 헬스케어 (쑤저우) 씨오., 엘티디. 항-trop2 항체 및 이의 접합체
CN117024438A (zh) * 2022-07-29 2023-11-10 杭州爱科瑞思生物医药有限公司 依沙替康衍生物及其应用
JP2025511436A (ja) * 2022-09-02 2025-04-16 メルク・シャープ・アンド・ドーム・エルエルシー エキサテカン由来トポイソメラーゼ－１阻害薬医薬組成物及びその使用
CN117752813A (zh) 2022-09-26 2024-03-26 成都百利多特生物药业有限责任公司 抗cd33抗体和抗cd33抗体-药物偶联物及其用途
EP4594327A1 (en) * 2022-09-30 2025-08-06 BeiGene Switzerland GmbH Ligand-drug conjugate of exatecan analogue, and medical use thereof
PE20252282A1 (es) 2022-10-09 2025-09-18 Lanova Medicines Ltd Compuestos, composiciones y metodos
CN120417935A (zh) 2022-10-25 2025-08-01 默沙东有限责任公司 依喜替康衍生的adc接头-载荷及其药物组合物和用途
EP4623936A1 (en) * 2022-11-22 2025-10-01 Keymed Biosciences (Chengdu) Co., Ltd. Fused ring compound, conjugate thereof and use thereof
KR20250106301A (ko) 2022-11-28 2025-07-09 쑤저우 선카디아 바이오파마수티컬즈 컴퍼니 리미티드 항-her3 항체-약물 접합체 조성물 및 이의 의약적 용도
WO2024131835A1 (en) * 2022-12-20 2024-06-27 Hansoh Bio Llc Ligand-cytotoxicity drug conjugates and pharmaceutical uses thereof
TW202434309A (zh) 2023-01-19 2024-09-01 大陸商上海盛迪醫藥有限公司 酪胺酸酶介導的蛋白定點偶聯及其應用
CN120344271A (zh) 2023-01-19 2025-07-18 江苏恒瑞医药股份有限公司 抗her2抗体药物偶联物治疗乳腺癌
IL322887A (en) 2023-02-27 2025-10-01 Suzhou Suncadia Biopharmaceuticals Co Ltd Anti-DLL3 antibody, antibody-drug conjugate and pharmaceutical use thereof
TW202502774A (zh) 2023-03-01 2025-01-16 大陸商江蘇恆瑞醫藥股份有限公司 一種茚并［１，２－ｂ］喹啉－１０，１３－二酮衍生物的製備方法
TW202438069A (zh) * 2023-03-30 2024-10-01 大陸商上海齊魯製藥研究中心有限公司 依喜替康衍生物及其抗體藥物偶聯物
KR20250174033A (ko) * 2023-04-23 2025-12-11 씨에스피씨 메가리스 바이오파마슈티칼 씨오., 엘티디. 항체 약물 접합체의 이용
TW202448934A (zh) 2023-04-28 2024-12-16 大陸商江蘇恆瑞醫藥股份有限公司 抗tf抗體和抗tf抗體-藥物偶聯物及其醫藥用途
WO2024227432A1 (zh) * 2023-04-30 2024-11-07 泰诚思(上海)生物医药有限公司 喜树碱衍生物、其制备方法及用途、抗体药物偶联物及其应用
CN121194979A (zh) * 2023-05-08 2025-12-23 甘李药业股份有限公司 喜树碱衍生物、接头、配体-药物偶联物及其医药用途
WO2024230742A1 (zh) 2023-05-08 2024-11-14 上海翰森生物医药科技有限公司 一种抗体或其抗原结合片段、抗体-药物偶联物及其应用
CN119522111A (zh) * 2023-05-16 2025-02-25 石药集团巨石生物制药有限公司 一种抗体药物偶联物的药物组合物
WO2024245382A1 (zh) * 2023-05-31 2024-12-05 甘李药业股份有限公司 依喜替康衍生物、及其配体-药物偶联物、抗体偶联物及用途
WO2024248123A1 (ja) 2023-06-02 2024-12-05 第一三共株式会社 抗ｈｅｒ３抗体－薬物コンジュゲートとｒａｓｇ１２ｃ阻害剤の組み合わせ
TW202521545A (zh) 2023-08-04 2025-06-01 大陸商江蘇恆瑞醫藥股份有限公司 抗ｐｓｍａ抗體－藥物偶聯物及其醫藥用途
WO2025031286A1 (zh) * 2023-08-04 2025-02-13 映恩生物制药（苏州）有限公司 抗体药物偶联物的识别抗体及其应用
WO2025061145A1 (zh) * 2023-09-22 2025-03-27 江苏恒瑞医药股份有限公司 抗her3抗体药物偶联物治疗肿瘤的用途和方法
CN120641100A (zh) * 2023-09-22 2025-09-12 台湾浩鼎生技股份有限公司 用于抗体耦合的改良型连接符-负载物、医药组合物、及其应用
WO2025087386A1 (zh) * 2023-10-25 2025-05-01 正大天晴药业集团南京顺欣制药有限公司 抗her2抗体药物偶联物治疗乳腺癌的用途
WO2025087358A1 (zh) * 2023-10-27 2025-05-01 上海翰森生物医药科技有限公司 抗体药物偶联物用于治疗癌症的方法
EP4548971A1 (en) 2023-11-06 2025-05-07 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin 1,4-benzothiazepines and related compounds with cyclopropanol groups as multi-targeted drugs
WO2025106278A1 (en) 2023-11-17 2025-05-22 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates
WO2025108438A1 (zh) * 2023-11-24 2025-05-30 江苏恒瑞医药股份有限公司 抗her3抗体药物偶联物和抗vegf抗体治疗肿瘤的方法
WO2025156953A1 (zh) * 2024-01-23 2025-07-31 上海池汐生物医药科技有限公司 一种多肽偶联物及其应用
WO2025176180A1 (zh) * 2024-02-23 2025-08-28 江苏恒瑞医药股份有限公司 艾日布林衍生物药物偶联物用于治疗肿瘤的用途
WO2025199665A1 (en) * 2024-03-23 2025-10-02 Ranok Therapeutics (Hangzhou) Co. Ltd. Methods and compositions for targeted protein degradation
WO2025209525A1 (zh) * 2024-04-03 2025-10-09 江苏恒瑞医药股份有限公司 抗cldn6抗体、其抗体-药物偶联物及其医药用途
WO2025228377A1 (zh) * 2024-04-29 2025-11-06 上海甫弘生物医药有限公司 B7-h3/egfr结合分子及其医药用途
WO2025242097A1 (zh) * 2024-05-21 2025-11-27 康诺亚生物医药科技（成都）有限公司 喜树碱类化合物及其偶联物和用途
WO2025252039A1 (zh) * 2024-06-03 2025-12-11 正大天晴药业集团股份有限公司 抗her2抗体药物偶联物治疗非小细胞肺癌的用途
WO2025252189A1 (zh) * 2024-06-06 2025-12-11 海思科医药集团股份有限公司 喜树碱类衍生物及其用途
WO2026046410A1 (zh) * 2024-09-02 2026-03-05 石药集团巨石生物制药有限公司 一种抗体药物偶联物与免疫检查点抑制剂的组合

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US6504029B1 (en) 1995-04-10 2003-01-07 Daiichi Pharmaceutical Co., Ltd. Condensed-hexacyclic compounds and a process therefor
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
PT1104760E (pt) * 1999-12-03 2003-06-30 Pfizer Prod Inc Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US7365205B2 (en) 2001-06-20 2008-04-29 Daiichi Sankyo Company, Limited Diamine derivatives
SI1545613T1 (sl) 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
CN101309917B (zh) * 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
US8257706B2 (en) 2006-08-25 2012-09-04 Seattle Genetics, Inc. CD30 binding agents and uses thereof
CN101573384B (zh) 2006-10-27 2013-02-20 健泰科生物技术公司 抗体和免疫偶联物及其用途
JP2015506349A (ja) 2011-12-21 2015-03-02 アルデリックス， インコーポレイテッド 非全身性ｔｇｒ５アゴニスト
DK2802325T3 (en) 2012-01-13 2017-03-13 Massachusetts Gen Hospital ANESTHETIC RELATIONS AND RELATED APPLICATIONS THEREOF
ES2690315T3 (es) 2012-06-15 2018-11-20 Mitsubishi Tanabe Pharma Corporation Compuestos de imidazol y triazol como inhibidores de DGAT-1
DK2907824T3 (en) 2012-10-11 2018-07-23 Daiichi Sankyo Co Ltd ANTIBODY-drug conjugate
EP2910573B1 (en) * 2012-10-19 2020-02-19 Daiichi Sankyo Company, Limited Antibody-drug conjugate produced by binding through linker having hydrophilic structure
SI2900277T1 (sl) * 2012-12-13 2022-05-31 Immunomedics, Inc. Odmerki imunokonjugatov protiteles in SN-38 za boljšo učinkovitost in zmanjšano toksičnost
SI3466976T1 (sl) 2014-01-31 2021-12-31 Daiichi Sankyo Company, Limited Anti-her2 konjugat protitelesa-zdravila
JP2017114763A (ja) * 2014-03-26 2017-06-29 第一三共株式会社 抗ｃｄ９８抗体−薬物コンジュゲート
JP6612738B2 (ja) * 2014-04-10 2019-11-27 第一三共株式会社 抗ｈｅｒ２抗体−薬物コンジュゲート
CN117138060A (zh) * 2014-10-07 2023-12-01 免疫医疗公司 抗体-药物缀合物的新辅助剂用途
MX2017010102A (es) 2015-02-15 2017-11-23 Jiangsu Hengrui Medicine Co Conjugado farmaco citotoxico-ligando, metodo de preparacion del mismo, y sus aplicaciones.
CN115969970A (zh) * 2016-02-10 2023-04-18 免疫医疗公司 Abcg2抑制剂与sacituzumab govitecan的组合
CN108853514B (zh) 2017-08-18 2022-07-22 四川百利药业有限责任公司 具有两种不同药物的抗体药物偶联物
CN112543771B (zh) * 2018-09-30 2023-04-11 江苏豪森药业集团有限公司 抗b7h3抗体-依喜替康类似物偶联物及其医药用途
MX2021014960A (es) * 2019-06-06 2022-03-04 Shanghai Hansoh Biomedical Co Ltd Conjugado de farmaco-anticuerpos anti-b7-h4 y uso medicinal del mismo.

Also Published As

Publication number Publication date
EP3858386A4 (en) 2022-10-12
KR20210066833A (ko) 2021-06-07
MX2021003382A (es) 2021-05-27
CN118903456A (zh) 2024-11-08
CN112512591B (zh) 2024-08-16
EP3858386A1 (en) 2021-08-04
JP2022511351A (ja) 2022-01-31
TWI826543B (zh) 2023-12-21
US20210353764A1 (en) 2021-11-18
CN119185572A (zh) 2024-12-27
WO2020063676A1 (zh) 2020-04-02
AU2019349207B2 (en) 2026-01-08
AU2019349207A1 (en) 2021-04-08
CN118806924A (zh) 2024-10-22
CN112512591A (zh) 2021-03-16
JP7558156B2 (ja) 2024-09-30
TW202027795A (zh) 2020-08-01
BR112021004656A2 (pt) 2021-06-01
CA3114137A1 (en) 2020-04-02
UA130338C2 (uk) 2026-01-28

Similar Documents

Publication Publication Date Title
ZA202102544B (en) Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof
PH12020551870A1 (en) Tetracyclic heteroaryl compounds
SA522433155B1 (ar) مركبات ثلاثية الحلقة مستبدلة
PH12020550341A1 (en) Niraparib formulations
MX389592B (es) Moduladores alostericos positivos del receptor m1 muscarinico
JOP20190183B1 (ar) معدِلات مستقبلات الاستروجين
ZA202002762B (en) Benzimidazole derivatives and their uses
MX2021010252A (es) Inhibidores del receptor de glucocorticoides.
WO2019054891A3 (en) Trpv2 antagonists
MX2020007985A (es) Inhibicion del canal ionico receptor de potencial transitorio a1.
PH12016500312A1 (en) 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
ZA202203421B (en) Modifier of four-membered ring derivative, preparation method and application thereof
NZ763341A (en) Polycyclic amides as muscarinic m1 receptor positive allosteric modulators
NZ740587A (en) Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators
PH12021553178A1 (en) Pyridin-3-yl derivatives
PH12021551396A1 (en) Active ester derivatives of testosterone, compositions and uses thereof
NZ764004A (en) Heteroaryl compounds as muscarinic m1 receptor positive allosteric modulators
PH12018502280A1 (en) Tetrahydropyran and thiopyran derivatives having multimodal activity against pain
GEAP202415862A (en) Alcohol derivatives as kv7 potassium channel openers
PH12018501563A1 (en) Indane derivatives as mglur7 modulators
MX2020000144A (es) Composicion farmaceutica para administracion nasal.
MX2018004774A (es) Derivados de morfolina sustituidos que tienen actividad contra el dolor.
MX2023000346A (es) Derivado de sulfonilbenzamida y conjugado del mismo, metodo de preparacion y uso del mismo.
MX2021004471A (es) Derivados de pirrolo-pididazina como moduladores alostéricos positivos del receptor muscarínico m1.
MX2015017124A (es) Combinacion de ro5503781, capecitabina y oxaliplatino para la terapia para el cancer.